肿瘤坏死因子α抑制药的围手术期管理

Perioperative Management of Tumor Necrosis Factor Alpha Inhibitors

肿瘤坏死因子α抑制药(TNFαi)作为抑制免疫系统、降低炎症水平的一类生物制剂,在自身免疫性疾病中的应用越来越广泛。但TNFαi理论上具有增加感染、肿瘤及其他并发症风险的可能,因此对于接受手术的患者,需权衡继续用药引起并发症发生率升高和暂停用药导致症状加重的相对风险,以提高围手术期用药安全性。目前中国尚无明确的临床指南指导TNFαi的围手术期管理,该文以类风湿关节炎、强直性脊柱炎、炎症性肠病、银屑病等适应证为出发点,系统梳理TNFαi在患者围手术期药物治疗中的使用建议与注意事项,以期为TNFαi的围手术期管理提供参考。

Tumor necrosis factor alpha inhibitors(TNFαi)are a class of biological agents that suppress the immune system and lower inflammatory levels,and they are increasingly employed to treat autoimmune diseases.However,TNFαi theoretically can increase the risk of infection,tumor,and other complications.To increase the safety of perioperative medicine,it is necessary to balance the relative risks of increased complication rates due to continuous medication and symptom aggravation due to medication suspension for patients undergoing surgery.Currently,there is no comprehensive clinical guideline for the perioperative management of TNFαi in China.To provide a reference for the perioperative management of TNFαi,this article used the indications of rheumatoid arthritis,ankylosing spondylitis,inflammatory bowel disease,and psoriasis as its starting point to systematically sort out the recommendations and considerations for the use of TNFαi in the perioperative drug treatment of patients.